171610
Anti-Amyloid Precursor Protein, C-Terminal (751-770) Rabbit pAb
liquid, Calbiochem®
Szinonimák:
Anti-0443, Anti-APP-CT20
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
Javasolt termékek
biológiai forrás
rabbit
Minőségi szint
antitest forma
serum
antitest terméktípus
primary antibodies
klón
polyclonal
form
liquid
faj reaktivitás
human
gyártó/kereskedő neve
Calbiochem®
tárolási körülmény
OK to freeze
izotípus
IgG
kiszállítva
ambient
tárolási hőmérséklet
−20°C
célzott transzláció utáni módosítás
unmodified
Általános leírás
Anti-Amyloid Precursor Protein, C-Terminal (751-770), rabbit polyclonal, recognizes full-length APP and C-terminal soluble products CTFα, β, and γ. It is validated for WB, IF, IHC, and IP.
Rabbit polyclonal antibody supplied as undiluted serum. Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).
Recognizes full-length APP and C-terminal soluble products CTFγ (~6 kDa), CTFα (~9 kDa), and CTFβ (~11 kDa).Antibody Target Gene Symbol: APP Target Synonym: AAA, AD1, Adap, AL024401, Amyloid precursor, Amyloidogenic glycoprotein, APP isoform 1, APPI, appican, CTFgamma, CVAP, E030013M08RIK, Nexin II, P3, PN2, PreA4, PROTEASE NEXIN2 Entrez Gene Name: amyloid beta (A4) precursor protein Hu Entrez ID: 351 (Related Antibodies: PC729, PC152,PC151, PC150, PC149, NE1012,171609, 171608, 171607, 171606, 171605, 171604, 171603, 171598, 171537) Mu Entrez ID: 11820 Rat Entrez ID: 54226
Immunogen
Human
a synthetic peptide [(C)KMQQNGYENPTYKFFEQMQN] corresponding to amino acids 751-770 of human precursor protein (APP), conjugated to KLH
Alkalmazás
Immunoblotting (1:5000-1:20,000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000)
Immunofluorescence (1:1000)
Immunohistochemistry (1:1000)
Immunoprecipitation (1:1000)
Figyelmeztetés
Toxicity: Standard Handling (A)
Feloldás
Following initial thaw, aliquot and freeze (-20°C).
Egyéb megjegyzések
Pinnix, I., et al. 2001. J. Biol. Chem.276, 481.
Variables associated with assay conditions will dictate the proper working dilution.
Jogi információk
Purchase of this material is for research use only. Users are invited to request a license from Mayo prior to using the 0433 antibody or any derivatives for clinical diagnostic or therapeutic purposes. For license information, please contact: Mayo Medical Ventures, Office of Technology Commercialization (507) 284-8878, 200 First Street SW, Rochester, MN 55905-001.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Nem találja a megfelelő terméket?
Próbálja ki a Termékválasztó eszköz. eszközt
Tárolási osztály kódja
10 - Combustible liquids
WGK
WGK 1
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Analitikai tanúsítványok (COA)
Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Neurobiology of disease, 36(1), 162-168 (2009-07-28)
The neuronal adaptor protein X11alpha/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11alpha in a mouse model of Alzheimer's disease (AD). We crossed hAPPswe/PS-1DeltaE9
Aging cell, 18(6), e13037-e13037 (2019-09-29)
Currently, there are no effective therapies to ameliorate the pathological progression of Alzheimer's disease (AD). Evidence suggests that environmental factors may contribute to AD. Notably, dietary nutrients are suggested to play a key role in mediating mechanisms associated with brain
Molecular psychiatry, 25(10), 2620-2629 (2019-01-10)
The lack of effective treatments for Alzheimer's disease (AD) is alarming, considering the number of people currently affected by this disorder and the projected increase over the next few decades. Elevated homocysteine (Hcy) levels double the risk of developing AD.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 25(12), 3032-3040 (2005-03-25)
Epidemiological studies suggest that increased intake of the omega-3 (n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). DHA levels are lower in serum and brains of AD patients, which could result
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 412-423 (2011-08-10)
Combined antiretroviral therapy (ART) tremendously improved the lifespan and symptoms associated with AIDS-defining illness in affected individuals. However, chronic ART-treated patients frequently develop age-dependent complications, including dementia, diabetes, and hyperlipidemia: all risk factors of Alzheimer's disease. Importantly, the effect of
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással